US Stock MarketDetailed Quotes

ALC Alcon

Watchlist
  • 84.170
  • -1.570-1.83%
Close Dec 13 16:00 ET
  • 84.170
  • 0.0000.00%
Post 20:01 ET
41.63BMarket Cap35.97P/E (TTM)

About Alcon Company

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Company Profile

SymbolALC
Company NameAlcon
Listing DateApr 9, 2019
Founded1945
CEOMr. David J. Endicott
MarketNYSE
Employees25315
Fiscal Year Ends12-31
AddressRoyce Bedward,Chemin de Blandonnet 8,Vernier
CityGeneva
ProvinceGeneve (Geneva)
CountrySwitzerland
Zip Code1214
Phone41-817-293-04-50

Company Executives

  • Name
  • Position
  • Salary
  • David J. Endicott
  • Director and Chief Executive Officer
  • 12.33M
  • Timothy C. Stonesifer
  • Chief Financial Officer
  • --
  • Sue-Jean Lin
  • Senior Vice President, Chief Information and Transformation Officer
  • --
  • F. Michael Ball
  • Chairman of the Board
  • 1.17M
  • Rajkumar Narayanan
  • President, International
  • --
  • D. Keith Grossman
  • Vice Chairman of the Board
  • 361.69K
  • Leon Sergio Duplan Fraustro
  • President, North America
  • --
  • Ian Bell
  • President, Global Business and Innovation
  • --
  • Lynn Dorsey Bleil
  • Independent Director
  • 296.31K
  • Karen J. May
  • Independent Director
  • 325.52K
  • Ines Poschel
  • Independent Director
  • 293.86K
  • Thomas H. Glanzmann
  • Independent Director
  • 352.98K
  • Scott H. Maw
  • Independent Director
  • 333.87K
  • Dr. Arthur Cummings, M.D.
  • Independent Director
  • 284.68K
  • Dr. Raquel C. Bono, M.D.
  • Independent Director
  • 256.66K
  • Dieter Spalti, PhD
  • Independent Director
  • 236.83K
  • Laurent Attias
  • Head, Corporate Development, Strategy, Business Development and Licensing and Mergers and Acquisitions
  • --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.